immatics.com - IMTX Income before deduction of interest, taxes and amortization

Graphic logo of Immatics NV (IMTX)

Strong management and partnerships with pharma giants create growth potential for Immatics N.V. (IMTX). The implementation of ESG standards and bioethics in production further supports this. The current EBITDA_Co level confirms the financial momentum, with the latest figure standing at 0.00. However, geopolitical fragmentation and logistical disruptions are limiting the conduct of global trials for new drugs.

Profit before payment of interest, taxes and amortization: Immatics N.V. (IMTX) for 11/23/2025 - 11/11/2026

Immatics - analytical breakdowns and key metrics (IMTX)

- market value and analyst target forecast:
Market Price Immatics Biotechnologies|IMTX - Consensus Target
- issuer market value details:
Market Value Immatics|IMTX - Enterprise Value
- book capitalization information:
Net Assets per Share Immatics|IMTX - Company Book Value|Market Cap to Net Assets Ratio immatics.com|IMTX - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Immatics N.V.|IMTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Immatics NV|IMTX - Company Debts|Debt to Book Value Ratio Immatics|IMTX - Company Long-Term Debt|Short-Term Debt Immatics|Critical Liquidity immatics.com
- company profitability and valuation multiples indicators:
IMTX - Net Income|Future Net Profit Immatics N.V.|IMTX - P/E Multiple|Future Price to Earnings Multiple immatics.com|IMTX - PEG Multiple|Company Value to EBITDA Immatics|IMTX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Immatics|IMTX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth immatics.com|IMTX - Earnings per share growth in current year|Net earnings per share change forecast for next year Immatics N.V.
Analysis of all company metrics:Immatics Biotechnologies - IMTX
Mass-produced product of Immatics

Absolute operating profit reflects the actual cash flow from core operations before depreciation and interest. For Immatics N.V. (IMTX), this metric demonstrates the efficiency of monetizing partnerships within the personalized cancer immunotherapy sector. Analyzing operating profit in cash terms allows for an assessment of the scaling pace of technological platforms. The trend of the curve reveals the business's ability to generate cash regardless of its debt load. Steady growth of this indicator confirms the high fundamental value of the assets.

Competitors of Immatics N.V. (IMTX)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Xencor, Inc. (XNCR)|Operating profit before deduction of amortization compasstherapeutics.com CMPX|Replimune - Operating profit before deduction of amortization|Operating profit EBITDA Lyell LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology, Inc.) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|Gritstone Bio - Operating profit EBITDA|Operating income before deduction of amortization kinetabio.com KA|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Turnstone Biologics Corp.|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before deduction of amortization Harpoon Therapeutics Corp (HARP)